The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells
Ziwei Li,Bin Li,Li Li,Guanying Wang,Yuanyuan Li,Ruoqiu Fu,Yue Ming,Rui Ni,Jiming Wang,George Ye,Jianhong Chen
DOI: https://doi.org/10.2147/OTT.S281397
IF: 4
2020-11-27
OncoTargets and Therapy
Abstract:Ziwei Li, 1, * Bin Li, 1, * Li Li, 1 Guanying Wang, 1 Yuanyuan Li, 1 Ruoqiu Fu, 1 Yue Ming, 1 Rui Ni, 1 Jiming Wang, 2 George Ye, 3 Jianhong Chen 1 1 Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, People's Republic of China; 2 Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; 3 Yes Biotech Laboratories Ltd, Mississauga, ON L5S 1V6, Canada *These authors contributed equally to this work Correspondence: Jianhong Chen Department of Pharmacy, Daping Hospital, Army Medical University, 10# Changjiangzhilu, Chongqing 400042, People's Republic of China Tel +86 23 6875 7098 Fax +86 23 6889 8867 Email chenjhlab@163.com Background: Monoclonal antibodies (mAbs) that target the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint have demonstrated substantial clinical benefit for a variety of solid tumors. However, their applications in patients with hepatocellular carcinoma (HCC) are reported with unclear molecular mechanisms. Here, we report a novel mouse anti-human PD-1 mAb that can reverse the immunosuppressive effect of HePG2 cells on Jurkat cells. Materials and Methods: HepG2 liver cancer cells, which were induced to overexpress PD-L1 by IFN-γ, were co-cultured with PHA-activated Jurkat lymphocytic cells to investigate the immunostimulative effect and mechanisms of the 14 newly generated PD-1 mAbs. Multiple cellular and molecular biology experiments were performed in this study, such as CCK-8, ELISA, flow cytometry, immunofluorescence and Western blot. Results: We found that mAb B1C4 significantly enhanced the tumor-killing cytokine secretion level by Jurkat cells in the co-culture system and increased the killing ability of Jurkat cells on HepG2 cells. Co-culture with HePG2 cells led to Jurkat cell cycle delay in S phase, and B1C4 promoted cell cycle progression from S to G2/M. Co-culture with HePG2 cells also caused apoptosis in Jurkat cells, which was inhibited by B1C4. B1C4 reversed the immunosuppression of Jurkat cells resulted from co-cultured with HePG2 cells through inhibiting PTEN and activating PI3K/AKT/mTOR signaling pathways. Conclusion: Our study demonstrated that anti-PD-1 mAb B1C4 could inhibit the apoptosis of Jurkat cells induced by HePG2 hepatoma cells and reverse the immunosuppressive effect of HePG2 cells on Jurkat cells. The study provides a vital basis for applying PD-1 monoclonal antibodies in the treatment of HCC and provides antibody selection for the development of novel PD-1 mAb with blocking activity. Keywords: hepatocellular carcinoma, monoclonal antibody, programmed cell death-1, PI3K/PTEN/AKT/mTOR signaling, T cell immunostimulation
oncology,biotechnology & applied microbiology